英国自动化与机器人供应商

BAE Systems plc

London

BAE Systems is the largest defense company in Europe and one of the top ten globally, formed in 1999 through the merger of British Aerospace and Marconi Electronic Systems. Headquartered in London, the company employs about 93,000 people across the UK, United States, Saudi Arabia, and Australia, and generates annual revenue of roughly GBP 25 billion from combat aircraft, naval ships, munitions, and electronic systems.\n\nBAE's combat aircraft business builds the Eurofighter Typhoon and is the lead contractor for the UK's next-generation Tempest fighter program under the Global Combat Air Programme with Italy and Japan. Its maritime division constructs and maintains the Royal Navy's Astute-class submarines and Type 26 frigates at yards in Barrow and Glasgow. In the United States, BAE Systems Inc. is a top-tier supplier of combat vehicles, artillery, and intelligence systems, while its Electronic Systems division provides the electronics backbone for F-35, including the aircraft's electronic warfare suite.\n\nFor suppliers, BAE offers some of the longest-horizon contracts in industry — submarine programs run 20+ years — but demands exacting quality standards: AS9100 aerospace certification, ITAR compliance, and secure digital supply chain integration are baseline requirements for its vendor base.

Linde plc

Guildford

Linde began with an academic problem: in the 1870s, Munich professor Carl von Linde was asked to improve the refrigeration used in breweries, and in 1877 he built the first reliable mechanical refrigeration machine — an invention that transformed the food and beer industries. From there, Linde moved into liquefying air itself, and that leap — separating oxygen, nitrogen, and argon from the atmosphere — created the modern industrial gas industry. Today Linde is the world's largest industrial gas company, supplying oxygen for steelmaking, nitrogen for electronics manufacturing, hydrogen for refineries, and the medical oxygen that hospitals rely on. Its on-site plants sit inside customer factories, producing gases continuously, while its pipelines serve industrial clusters; its electronics division supplies the ultra-high-purity gases and materials used in semiconductor fabrication. Linde's modern form came from the 2018 merger with US rival Praxair — one of the largest industrial mergers ever — creating a company with about 65,000 employees and annual revenue near US$33 billion. Based in Woking, UK (with US operations headquartered in Danbury, Connecticut), Linde competes with Air Liquide and Air Products, and its engineering arm still designs the air separation units that rival gas makers themselves buy.

Rolls-Royce Holdings plc

London

Rolls-Royce Holdings is a British aerospace and defense company, the world's second-largest maker of aircraft engines for wide-body commercial jets and a global leader in marine propulsion and nuclear power systems. The company's aviation roots date to 1906, when Charles Rolls and Henry Royce founded the original Rolls-Royce; the modern company was formed through nationalization of the aero-engine business in 1971 and re-privatization in 1987. It is headquartered in London and employs about 42,000 people. Rolls-Royce's Trent family of engines powers Airbus A330, A350, A380, and Boeing 787 aircraft, while its Power Systems division (MTU) builds diesel engines and gensets for marine, rail, and defense customers. The company is also a leader in small modular reactors (SMRs) for nuclear power and in all-electric and hybrid aerospace propulsion research. For aerospace and defense supply chains, Rolls-Royce is a prime customer for turbine blades, castings, forgings, and electronic controls, and a supplier of high-value engines and power systems with one of the industry's largest aftermarket service networks.

AstraZeneca plc

Cambridge

AstraZeneca is one of the world's largest biopharmaceutical companies, created in 1999 by the merger of Sweden's Astra AB and the UK's Zeneca Group, and headquartered in Cambridge, England. The company employs about 90,000 people and generates annual revenue of roughly US$45 billion, with three therapeutic pillars: oncology, cardiovascular/renal/metabolic disease, and respiratory & immunology.\n\nAstraZeneca's oncology franchise is anchored by Tagrisso (osimertinib) for EGFR-mutated lung cancer, Imfinzi (durvalumab) for immunotherapy, and Enhertu, a breakthrough antibody-drug conjugate developed with Daiichi Sankyo that is reshaping breast-cancer treatment. The company also built a global vaccines business through the COVID-19 pandemic, developing one of the first widely deployed vaccines with the University of Oxford, and maintains manufacturing sites across the UK, Sweden, the United States, China, and Singapore.\n\nFor pharmaceutical supply chains, AstraZeneca is a major buyer of active pharmaceutical ingredients, biologics raw materials, glass vials, and packaging, with stringent GMP standards, and its global manufacturing network creates stable, long-term procurement demand for specialty chemical and life-science suppliers.